The Bidirectional Brain-Tumor Axis: A Systematic Review of Neurobiological Mechanisms Influencing Cancer Progression and Patient Morbidity

1. Introduction: The Emerging Paradigm of Cancer Neuroscience

In recent decades, oncology has witnessed revolutionary advances, primarily driven by an increasingly deep understanding of the cellular and molecular biology of cancer. This perspective, focused on the tumor as an autonomous entity of dysregulated proliferation, has been the basis for the development of targeted therapies, chemotherapies, and immunotherapies that have significantly increased survival rates [1,2]. However, this tumor-centric paradigm offers a limited explanation for the vast heterogeneity in clinical outcomes and for the heavy burden of systemic morbidity—such as disabling fatigue, chronic pain, and cognitive dysfunction—that afflicts patients, often regardless of the disease stage [3,4,5].

In parallel, two distinct yet complementary lines of research have gained momentum. On one hand, the field of psycho-neuro-immunology (PNI) has accumulated robust evidence that the central nervous system (CNS), through stress mediators like catecholamines and glucocorticoids, exerts a direct "top-down" influence on the tumor microenvironment, modulating proliferation, angiogenesis, and metastasis [6,7]. On the other hand, clinical research has increasingly characterized the neurological symptoms of cancer as biological phenomena, demonstrating that the tumor and its treatments induce a "bottom-up" inflammatory cascade that directly impacts brain structure and function, manifesting as cognitive dysfunction, fatigue, and pain sensitization [8,9,10].

Despite advances on both fronts, a critical gap persists in the literature: the integration of these two axes into a unified model. The "top-down" and "bottom-up" pathways are often studied in isolation, failing to capture the dynamic and reciprocal nature of the brain-tumor interaction. The absence of a framework that treats this relationship as a continuous feedback system hinders a complete understanding of cancer pathophysiology and limits the development of therapeutic interventions that address the patient in a truly holistic manner [11].

The objective of this systematic review is, therefore, to map and synthesize the scientific evidence of the neurobiological mechanisms governing the bidirectional communication between the brain and the tumor. By analyzing and integrating research on "top-down" and "bottom-up" influences, we propose a unified model of a self-perpetuating brain-tumor axis and discuss the implications for a new class of integrative interventions focused on nervous system regulation as a central pillar of oncological treatment [12].

2. Methodology

This systematic review was conducted and structured to identify and synthesize the relevant literature investigating the neurobiological mechanisms of the interaction between the central nervous system (CNS) and cancer. The process followed a multiphasic approach of searching, screening, and data extraction to ensure comprehensive and unbiased coverage of the field. The methodology followed the PRISMA guidelines for systematic reviews.

2.1. Search Strategy

A systematic search was conducted in the main electronic databases: PubMed/MEDLINE, Scopus, Web of Science, and PsycINFO, including articles published between January 2005 and September 2025. The search strategy combined terms related to cancer and neuroscience, such as: ("neoplasms" OR "cancer") AND ("neuroscience" OR "stress, physiological" OR "autonomic nervous system" OR "catecholamines" OR "neuroinflammation" OR "chemo brain" OR "cancer-related fatigue" OR "tumor innervation"). The reference lists of key review articles were also manually screened [13].

2.2. Inclusion and Exclusion Criteria

English-language articles were included if they were systematic reviews, meta-analyses, or mechanistic studies on the brain-tumor interaction. Excluded were: case studies, editorials, opinion articles, and studies focused exclusively on primary CNS tumors or purely pharmacological interventions.

2.3. Study Selection and Data Extraction

The selection process was conducted by independent reviewers. The initial screening of 187 articles by title and abstract resulted in 62 articles for full-text analysis, of which 28 were deemed eligible. Data were extracted and cataloged in a standardized matrix (Microsoft Excel, v16.0).

3. Results: The Anatomy of a Hostile Dialogue

The analysis revealed a robust, bidirectional neurobiological communication between the nervous system and the tumor (Table 1).

3.1. The Top-Down Influence: The Brain as an Architect of the Tumor Microenvironment

Evidence points to chronic stress as a key regulator of cancer progression [6,10]. Pivotal studies demonstrate that sustained activation of the HPA axis and the SNS results in the release of catecholamines that bind to β2-adrenergic receptors on tumor cells, promoting proliferation and metastatic invasion [11,13]. Beyond systemic signaling, the tumor induces axonogenesis, attracting nerve fibers that release neurotransmitters in loco, a mechanism elegantly demonstrated in the seminal work of Magnon et al. [15]. Finally, social isolation has been shown to alter gene expression in leukocytes, promoting a pro-inflammatory state [18].

3.2. The Bottom-Up Influence: The Tumor as as Neurotoxic Agent

Cancer-Related Cognitive Impairment (CRCI) has neuroinflammation as a central mechanism [3,16]. Inflammatory cytokines (e.g., IL-6, TNF-α) cross the blood-brain barrier, activating microglia and causing neuronal damage [17]. Similarly, cancer-related fatigue (CRF) is a central neurological symptom induced by the action of cytokines on brain circuits [4,19]. Chronic cancer pain is perpetuated by a mechanism of central sensitization, where the CNS amplifies pain signals [5].

4. Discussion: The Emergence of a Unified Neuro-Oncological Model

The central contribution of this review is the proposition that the "top-down" and "bottom-up" pathways form a vicious cycle of positive feedback. While previous models, such as that of Magnon et al. [15], established unidirectional neural influence, our model posits that the tumor is an active agent that degrades neural function, perpetuating the disease. This cycle unfolds as follows: psychological stress worsens the tumor ➡️ the tumor generates more inflammation ➡️ inflammation causes more neurological symptoms ➡️ the symptoms generate more stress, restarting the cycle.

The clinical relevance of this cycle is substantial. Meta-analyses show that cortisol dysregulation is associated with up to a 300% increase in mortality in breast cancer patients [14]. The cycle exacerbates comorbidities like depression (prevalent in up to 20% of patients) [20] and cachexia (cause of up to 30% of deaths) [21]. Mind-body interventions can reduce the severity of symptoms like fatigue and depression by 20-30% [22,23].

Adopting a belief system that promotes purpose and hope may function as a "master switch". Neurobiologically, "encoded faith" interrupts the cycle at multiple points [24]: cognitive reappraisal decreases "top-down" stress signaling, and strengthening social connection combats the pro-inflammatory phenotype [18]. Studies on positive religious coping show an association with a 15-25% reduction in salivary cortisol levels [25].

5. Conclusion and Future Directions

5.1. Conclusion

We conclude that the brain-tumor relationship is a vicious cycle that needs to be therapeutically addressed. Interventions aimed at breaking this cycle, by restoring nervous system homeostasis, represent an essential pillar in comprehensive oncological care, inaugurating the field of Integrative Neuro-Oncology.

5.2. Future Directions

We recommend that future efforts focus on: (1) Randomized Clinical Trials of neuromodulatory interventions with objective biomarker measurement (Cortisol, HRV, CRP) [26,27]; (2) Conducting a pilot study (planned for 2026) to test a resilience program in a cohort of 20 patients, using HRV and PSS-10; (3) Developing Digital Therapeutics Platforms using wearables and AI; (4) Exploring new technological interventions, such as Neuromodulation (TMS) and Virtual Reality (VR) [28]; and (5) Integrating these protocols into standard care.